The high technological complexity of products and services is a feature of the health sector. Therefore, the relationship between the scientific base of universities and institutes and the pharmaceutical industry is a necessary condition for national technological advances in this segment. One strategy already adopted and consolidated by the countries that are at the cutting edge of technological development and that, from the advent of the Innovation Law - Law 10.973/2004 - has been increasingly embraced by Brazilian institutions and Fiocruz is one of the most prominent health institutions from Brazil immersed in the research innovation challenges.
Fiocruz produces, disseminates, and share knowledge and technologies and contributes to the promotion of health and quality of life of the population.
Besides the reduction of social inequalities and the national dynamics of innovation, with the defense of the right to health and full citizenship as central values, it uses science and innovation as the basis of socio-economic development and health promotion.
COVID 19, HIV-1, HIV-1 / 2, Chagas’ disease, dengue fever, leishmaniasis, leptospirosis, arboviruses, influenza, and many other diseases are under research at Instituto Oswaldo Cruz. Please take a look at the technological showcase in COVID 19, shared in the links to the research work window.